The Gabrail Cancer Center currently has many Clinical Trial opportunities. For more information and to see if you qualify call Carrie Smith R.N., Director of Research at 330-492-3345 x 208 or email CSmith@GabrailCancerCenter.com.
A Phase III, Multicenter, Randomized,Open-Label Study Evaluating the Efficacy and Safety of Inavolisib Plus Fulestrant Versus Alpelisib Plus Fulvestrant in Patients with Hormone Receptor-Postitive, HER2-Negative, PIK3CA Mutated, Locally Advanced or Metastatic Breast Cancer who Progressed During or after CDK4/6 Inhibitor and Endocrine Combination Therapy
Phase 1b/2 Study of the Addition of STAT3 Inhibitor TTI-101 to Reverse Resistance on First Line Palbociclib Plus Aromatase Inhibitor Therapy for Metastatic Hormone Receptor-Positive and HER2-Negative Breast Cancer
An Open-label Multicenter Phase 1b-2 Study of Elacestrant as Monotherapy and in Combination with Abemaciclib in Women and Men with Brain Metastasis from Estrogen Receptor Positive, HER-2 Negative Breast Cancer (ELECTRA)
A Phase III, Randomized, Open-label, Multicenter Study Evaluating the Efficacy and Safety of Giredestrant plus Everolimus Compared with Exemestane plus Everolimus in Patients with Estrogen Receptor-Positive, HER2-Negative, Locally Advanced or Metastatic Breast Cancer